trump glp-1 deal Novo, Lilly cut with to lower prices of obesity drugs Questions swirl after Trump's GLP-1

[DOI] [PubMed] [Google Scholar] Murano S (1995)

Very aggressive deficits are typically short-term and not recommended for long periods, because they can strain your metabolism and lead to muscle loss or nutritional deficiencies if not carefully managed

GLP-1 medications also carry some serious (but rare) warnings: Potential risk of thyroid C-cell tumors (observed in rodent studies, unclear relevance in humans) Risk of gallbladder problems Pancreatitis (rare but documented) Hair loss (temporary, related to rapid weight loss rather than the drug itself) One notable advantage of GLP-1 medications: they do not cause cognitive dysfunction, do not carry teratogenicity warnings as severe as topiramate, and are not controlled substances

Ozempic and Rybelsus are not FDA approved to treat type 2 diabetes